Lung cancer has become an immediate concern and reviewing the side effects associated with conventional chemotherapy, with the advent of nanobiomedicine, various nanoformulations are being researched. In the current study, our team has investigated aerosolized dry inhaler powder loaded with a combination of two potent anti-cancer drugs, cisplatin and paclitaxel for locoregional delivery of the same to the lung tissues. This nanoformulation has been investigated by morphological analysis and in-vitro studies to ensure proper therapeutics. Its efficacy has been determined by the anti-tumor studies. The size of the DPIs have been found to be in the range of 60–85 nm small enough to escape the clearance mechanisms in the pulmonary route. The nanoformulations with size < 200 nm easily move to the tumor vasculature which has been exploited completely here. The fine particle fraction (< 5 µm) deposited in the lungs was found to be 50%. They were also associated with reduced toxicity and they efficiently reduced the tumor volume by 75%. Therefore we may safely conclude that the current formulation overcomes the striking hindrances of nanocomposites namely increased toxicity, higher clearance from system and low efficacy due to inefficient targeting of drug.

肺癌已成为当务之急，回顾与常规化疗相关的副作用，随着纳米生物医学的出现，正在研究各种纳米制剂。在目前的研究中，我们的团队研究了装有两种强效抗癌药物顺铂和紫杉醇的气雾化干吸入器粉末，用于将其局部递送至肺组织。这种纳米制剂已经通过形态分析和体外研究进行了研究，以确保适当的治疗。其功效已由抗肿瘤研究确定。已发现 DPI 的大小在 60-85 nm 的范围内，小到足以逃脱肺通路中的清除机制。尺寸 < 200 nm 很容易移动到这里已经完全利用的肿瘤脉管系统。发现沉积在肺部的细颗粒部分 (< 5 µm) 为 50%。它们还与降低的毒性有关，它们有效地将肿瘤体积减少了 75%。因此，我们可以肯定地得出结论，目前的配方克服了纳米复合材料的显着障碍，即由于药物靶向性低下导致的毒性增加、系统清除率较高和功效低。